

J. Med. Chem. Sci. 2 (2019) 172-176Journal homepage: <http://jmchemsci.com>**An Overview on Fluoroquinolone Drugs for the Treatment of Tubercular Infection**

Mohammad Asif *

Department of Pharmacy, GRD (PG) IMT, Dehradun, (Uttarakhand), 248009, India.

ARTICLE INFO*Article history:*

Received: 21 December 2018

Revised: 21 February 2019

Accepted: 14 March 2019

Keywords:

Fluoroquinolones

Levofloxacin


Moxifloxacin

Gatifloxacin


Tuberculosis

ABSTRACT


The fluoroquinolones-levofloxacin, moxifloxacin and gatifloxacin have potent bactericidal activities against *Mycobacterium tuberculosis*. They have the potential activity in managing both drug-susceptible and drug-resistant tuberculosis as well as the possibility of shortening the period of therapy. The emergence of drug-resistance, fluoroquinolone-resistant, multidrug-resistant and extensively drug-resistant tuberculosis created a challenge to control the tuberculosis globally. The newer fluoroquinolones have clinical efficacy in some of the patients. So, the utility of new fluoroquinolone drugs for the treatment of tuberculosis is needed.

ABSTRACT


Moxifloxacin




Gatifloxacin




Sparfloxacin



Ciprofloxacin



Enrofloxacin


R/S: Ofloxacin
S: Levofloxacin**1. Introduction**

Quinolones are synthetic drugs synthesized by structural modification of the 4-oxo-1, 4 dihydroquinolone nucleus or the 1, 8 naphthyridone nucleus. Fluorination of these basic molecules, usually at position 6, resulted in the fluoroquinolones (FQs). Levofloxacin is the S(-) enantiomer of the parent racemic compound ofloxacin, whereas moxifloxacin and gatifloxacin are regarded as later generation C-8-methoxy FQs. The levofloxacin, moxifloxacin and gatifloxacin are newer FQs that have potent antituberculosis (anti-TB) activity, much of which is due to the

C-8-methoxy moiety.¹⁻³ An comprehensive review addressed the efficacy of FQs in TB, together with patient tolerability/safety, for the following indications-(i) first-line treatment of drug-susceptible (DS) pulmonary TB, (ii) first-line treatment of multidrug-resistant (MDR) TB and (iii) treatment of patients with intolerance to standard first-line anti-TB drugs.⁴ The data were insufficient to support the use of older FQs, especially ciprofloxacin, as substitute agents for DS or DR-TB. This view was also shared FQs used for treating TB.⁵ The role of FQs in treating TB is largely restricted to levofloxacin, moxifloxacin and gatifloxacin.

FQs for the treatment of MDR-TB

The MDR-TB has confirmed the dose-dependent efficacy of ofloxacin in the treatment of TB and the 800 mg once-daily dose was found to be superior to the 300 mg once-daily dose, achieving a more rapid and higher proportion of culture negativity. The use of FQs (ofloxacin and ciprofloxacin) for the treatment of MDR-TB have emerged⁶⁻⁹, with success rates



The six standardized treatment regimens for MDR-TB¹¹, the most effective treatment regimen required a minimum duration of nine months with gatifloxacin, clofazimine, ethambutol, and pyrazinamide supplemented by prothionamide, kanamycin and high-dose isoniazid during an intensive phase of a minimum of four months, giving a relapse-free success rate of 87.9%. The treatment success rate for the earlier ofloxacin-containing regimen was only 69.0%.¹² The combination of amikacin, ethionamide, moxifloxacin and pyrazinamide has shown good efficacy.¹³ In the use of moxifloxacin for MDR-TB, the treatment success rate was only 51.7%.¹⁴ There was no clear report of the chemotherapy response rate for several patients with MDR-TB.¹⁵ The optimal duration of treatment for MDR-TB using a FQs-containing regimen is currently unknown. It was successfully improved when the length of treatment was at least 18 months, and if patients received directly observed therapy throughout.¹⁶ However, some patients could be adequately treated with newer FQs for shorter periods to achieve a relapse-free cure.

The FQ resistance in *Mycobacterium tuberculosis* (Mtb) can emerge following the injudicious use of this class of drugs, especially in the setting of MDR-TB, alongside the suboptimal use of accompanying drugs too few in numbers and/or too low a dosage.^{17, 18} Poor drug quality can also be an issue. Overzealous use of FQs in the treatment of infections of the lower respiratory tract and other origins might also contribute to the development of FQR-TB.¹⁹ As aminoglycosides/capreomycin also have potent anti-TB activity, the “loss” of these second-line injectable preparations together with FQs, through their suboptimal use in the treatment of MDR-TB, would result in the development of extensively drug-resistant (XDR) TB.²⁰ This latter disease poses an even more “complicated” scenario of drug resistance than FQR, MDR-TB, and is generally linked with a treatment success rate of 50% or less.²¹ A analysis of the treatment outcomes and survival based on drug resistance patterns in MDR-TB strongly underscores the appropriateness of the definition XDR-TB and its association with a dismal prognosis.²²

usually around 70%. A study on MDR-TB has shown that the use of FQs was independently linked to the improved initial microbiological outcome, as well as survival from all causes of death.¹⁰ The pivotal role of the FQs in the chemotherapy of MDR-TB.

The potential usefulness of levofloxacin in treating DR-TB²³, a comparison between ofloxacin and levofloxacin²⁴ has also revealed that the latter FQ, when substituting for the former, in regimens with similar accompanying drugs, resulted in higher success rates for both ofloxacin-susceptible (96.2% vs. 87.5%) and ofloxacin-resistant (78.6% vs. 45.5%) MDR-TB treatment. Thus, levofloxacin is quite likely to be more efficacious than ofloxacin when included in multidrug regimens for treating MDR-TB, including the “difficult” forms.

The C-8-methoxy FQs-moxifloxacin and gatifloxacin might also have activity against ofloxacin-resistant *Mtb* isolates, including those that are MDR, notwithstanding the phenomenon of partial cross-resistance among members of the FQ class.^{25, 26} Indeed, these two newer FQs have lower mutant prevention concentrations for *Mtb* and should have a greater potential to restrict the development of bacillary resistance.²⁷ However, it appears that for efficient suppression of development of DR-TB, high-dose moxifloxacin is preferable, but could well be limited by intolerability.²⁸ In a meta-analysis on the treatment outcomes of patients with XDR-TB²⁹, 43.7% exhibited a cure or treatment completion.

Newer FQs for the treatment of DS-TB

The most commonly encountered indication for the use of FQs in the current practice is intolerance to standard first-line anti-TB drugs, especially due to hepatic dysfunction.⁴ Although some patients can be satisfactorily returned to the originally scheduled first-line drug regimen, most affected patients require the use of a relatively non-hepatotoxic regimen, on an in-terim or definitive basis.³⁰ Earlier reports on this subject largely involved ofloxacin, used in conjunction with streptomycin, and ethambutol.³¹ In case of definitive treatment of TB, ofloxacin/levofloxacin can be used together with isoniazid/rifampicin, plus perhaps even low-dose pyrazinamide, depending on the liver reserve.³¹ A retrospective study of a cohort of tuberculosis patients with liver injury prescribed an alternative therapeutic regimen

consisting of three months of streptomycin, ethambutol and ofloxacin, followed by nine months of ethambutol and ofloxacin. This alternative regimen proved well tolerated by the patients, and was effective in 85%.³² In another study involving patients who developed hepatotoxicity to first-line anti-TB drugs, the use of levofloxacin and moxifloxacin caused no additional hepatic insult, and allowed smooth normalization of liver transaminases similar to the control patients.³³ Hepatotoxicity due to first-line anti-TB drugs has been found to be particularly frequent among patients with solid-organ transplants³⁴, perhaps largely due to immunocompromization and the toxicity of anti-rejection drugs. The use of regimens containing ofloxacin/levofloxacin was especially beneficial. Aside from good tolerance, the lack of drug interactions proved to be advantageous. Random regimens could not be used.³⁵ Other serious intolerance to standard first-line anti-TB drugs is rare. Important examples include agranulocytosis³⁶, thrombocytopenia³⁷ and renal failure.³⁸

Levofloxacin use in these patients has produced a good outcome

Aside from intolerance to conventional anti-TB drugs, the newer FQs may find a place in increasing the efficacy of anti-TB drug regimens due to their potent activity. Theofloxacin/levofloxacin penetrates the pleural cavity better than rifampicin (>10-fold) and, thus, helps to strengthen the first-line therapy for TB empyema³⁹, although such efficacy following the addition of a FQ to the treatment is lacking. Moxifloxacin-containing regimens demonstrated a greatly reduced time to culture conversion⁴⁰, and a short treatment with such a regimen produced a stable cure.⁴¹ Based on these findings, the significant sterilizing activity of moxifloxacin might enable a shortening of the length of therapy for drug-susceptible TB. A report from India suggested the potential usefulness of ofloxacin for shortening the length of treatment of DS-TB⁴². The addition of moxifloxacin to isoniazid, rifampicin and pyrazinamide did not affect the two-month sputum culture status, but there was increased activity at earlier time points.⁴³ Using serial sputum colony counting by non-linear mixed effects modeling, moxifloxacin substitution for ethambutol appeared superior during the early phase of a bi-exponential fall in colony counts, but a significant and similar acceleration of bacillary elimination during the late phase occurred with both moxifloxacin and gatifloxacin.⁴⁴ At eight weeks, culture conversion to negative occurred in 80% patients in the moxifloxacin group, compared with 63% patients in the ethambutol group.⁴⁵ Substituting moxifloxacin for isoniazid only showed a non-significant effects meta-analysis and meta-regression showed that studies in which a higher proportion of patients received a later-generation FQ (levofloxacin, moxifloxacin or sparfloxacin) reported a higher proportion of favourable treatment outcomes.²⁹ This is interesting because it seems that later-generation FQs could improve the treatment success of XDR-TB, even though drug susceptibility testing had demonstrated bacillary resistance to a representative FQ. This issue should be systematically evaluated in well designed clinical trials.

Other issues regarding the use of newer fluoroquinolones in tuberculosis

The commonest side effects of moxifloxacin use are GI disturbance and neurological dysfunction.⁴⁶ In addition, there is preincrease in sputum culture conversion at week 8.⁴⁶ Adding moxifloxacin to the four standard first-line anti-TB drugs shortened the time to culture conversion, and the culture conversion rate after six weeks of treatment rose from 61% to 82%.⁴⁷ Substitution of moxifloxacin for isoniazid can reduce the current length of therapy of DS-TB to four months. The OFLOTUB consortium is also investigating a four-month regimen based on gatifloxacin. Although an early bactericidal activity (EBA) study has shown significant results with moxifloxacin in patients with pulmonary TB⁴⁸, the early and extended EBA of levofloxacin, alongside that of moxifloxacin and gatifloxacin, has shown that levofloxacin 1,000 mg daily produced potent EBA comparable with that of isoniazid, and better than that of moxifloxacin and gatifloxacin.⁴⁹ Weekly moxifloxacin and rifapentine has been shown to be more active than twice-weekly rifampicin and isoniazid in a mouse tuberculosis model.⁵⁰ Daily dosing of rifapentine cured the disease in three months or less.⁵¹ A controlled clinical trial using high-dose rifapentine and moxifloxacin (RIFAQUIN) is now in progress. The rate of any major adverse events in those who used levofloxacin (because of DR-TB or intolerance to first-line anti-TB drugs) was almost half that in those who received standard therapy.⁵² Furthermore, there was no difference between the levofloxacin and control arms with respect to central nervous system, gastrointestinal (GI) tract, skin or musculoskeletal related events when adjusted for the concomitant drugs. These findings strongly corroborate those from observational and other studies of the levofloxacin treatment of TB. However, it might be useful to remember some rare side effects related to ofloxacin/levofloxacin use including arthropathy, fungal superinfection and antibiotic-related colitis.⁵³

Safety/tolerance of newer FQs

The beneficial use of moxifloxacin in treating TB in human immunodeficiency virus (HIV)-infected patients when conventional arrhoea was found to be modest after controlling for sex, age, other antibiotic use, serum albumin, duration of hospital stay and nasogastric feeding⁽⁵⁴⁾. Although the risk for potential cardiotoxicity is perhaps higher for moxifloxacin, as compared to levofloxacin⁽⁵⁵⁾, a randomized trial involving the cardiac rhythm safety of moxifloxacin versus levofloxacin in elderly patients with community-acquired pneumonia has shown them to have a comparable risk and safety.⁵⁶ However, it is important to remember that this may not be the case when considering long-term use of these FQs in the treatment of TB. Extreme caution must thus be exercised in patients with underlying cardiac diseases or QTc prolongation, especially for those with risk factors for torsades de pointes. Gatifloxacin use is associated with GI and neurological adverse reactions like moxifloxacin. It also has potential cardiotoxicity.⁵⁷ However, most importantly, it is associated with dysglycaemia⁵⁸, especially in older patients.

Despite the promise of the newer FQs in the future treatment of TB, such optimism is somewhat tempered by the escalating rates of FQ resistance in *Mtbin* many parts of the

world, especially in countries with a high incidence of TB.⁵⁹ Empirical use of the newer FQs may also mask the diagnosis of TB, with a resultant delay in the start of treatment and a poor outcome.⁶⁰ Another concern is the interaction of moxifloxacin and gatifloxacin with rifampicin, resulting in potential attenuation of the efficacy of the former FQ⁶¹, and a potentially increased risk of toxicity for the latter FQ.⁶²⁻⁶⁷

Conclusions

Preliminary evidences clarified that levofloxacin might have immunomodulating potential in addition to anti-TB activity and, if properly harnessed, this could have therapeutic implications. The newer fluoroquinolones have good bactericidal and sterilizing activities against *Mtb*. They could support the existing antibiotic armamentarium for the therapeutic control of drug-resistant and drug-susceptible tuberculosis. The potential adverse aspects were associated to their use in the disease. Thus, further exploration and evaluation are still needed in order to develop optimum regimens.

References

- L. Fattorini, D. Tan, E. Iona, M. Mattei, F. Giannoni, L. Brunori, S. Recchia, G. Orefici, *Antimicrob Agents Chemother*, **2003**, 47:360
- M. Asif, *Orien Pharm & Experi Med.*, 2012, 12, 15.
- M.A. Asif, *Mini. Rev. Med. Chem.*, **2012**, 12:1404
- S. Moadebi, C.K. Harder, M.J. Fitzgerald, K.R. Elwood, F. Marra, *Drugs* **2007**, 67:2077
- M. Asif, A.A Siddiqui, A. Husain, *Med. Chem. Res.*, **2013**, 22:1029
- W.W. Yew, C.K. Chan, C.H. Chau, C.M. Tam, C.C. Leung, P.C. Wong, J. Lee, *J. Chest.*, **2000**, 117: 744
- K. Tahaog'lu, T. Törün, T. Sevim, G. Ataç, A. Kir, L. Karasulu, I. Ozmen, N. Kapakli, *N. Engl. J. Med.*, **2001**, 345:170
- V. Leimane, V. Riekstina, T.H. Holtz, E. Zarovska, V. Skripconoka, L.E. Thorpe, K.F. Laserson, C.D. Wells, *Lancet*, **2005**, 365:318
- C.Y. Chiang, D.A. Enarson, M.C. Yu, K.J. Bai, R.M. Huang, C.J. Hsu, J. Suo, T.P. Lin, *Eur. Respir. J.*, **2006**, 28:980
- E.D. Chan, V. Laurel, M.J. Strand, J.F. Chan, M.L. Huynh, M. Goble, M.D. Ise-man, *Am. J. Respir. Crit. Care Med.*, **2004**, 169:1103
- A. Van Deun, A.K. Maug, M.A. Salim, P.K. Das, M.R. Sarker, P. Daru, H.L. Rieder, *Am. J. Respir. Crit. Care Med.*, **2010** May 4; [Epub ahead of print].
- A. Van Deun, M.A. Salim, A.P. Das, I. Bastian, F. Portaels, *Int. J. Tuberc. Lung Dis.*, **2004**, 8:560
- N. Lounis, N. Veziris, A. Chauffour, C. Truffot-Pernot, K. Andries, V. Jarlier, *Antimicrob Agents Che-mother*, **2006**, 50:3543
- L.R. Codecasa, G. Ferrara, M. Ferrarese, M.A. Morandi, V. Penati, C. Lacchini, P. Vaccarino, G.B. Migliori, *Respir Med.*, **2006**, 100:1566
- G. Valerio, P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, S. Bel-lanova, *J. Chemother.*, **2003**, 15:66
- E.W. Orenstein, S. Basu, N.S. Shah, J.R. Andrews, G.H. Friedland, A.P. Moll, N.R. Gandhi, A.P. Galvani, *Lancet Infect. Dis.*, **2009**, 9:153
- J.Y. Wang, L.N. Lee, H.C. Lai, S.K. Wang, I.S. Jan, C.J. Yu, P.R. Hsueh, P.C. Yang, *J. Antimicrob Chemother*, **2007**, 59: 860
- J.A. Caminero, *Int. J. Tuberc. Lung Dis.*, **2008**, 12:869
- R.A. Devasia, A Blackman, T Gebret-sadik, M Griffin, A Shintani, C May, T Smith, N Hooper, F Maruri, J Warkentin, E Mitchel, TR Sterling, *Am J Respir Crit Care Med.*, **2009**, 180: 365
- G.B. Migliori, C. Lange, R. Centis, G. Sotgiu, R. Mütterlein, H. Hoffmann, K. Kliiman, G. De Iaco, F.N. Lauria, M.D. Richardson, A. Spanevello, D.M. Cirillo, *Eur. Respir J.*, **2008**, 31:1155
- H.R. Kim, S.S. Hwang, H.J. Kim, S.M. Lee, C.G. Yoo, Y.W. Kim, S.K. Han, Y.S. Shim, J.J. Yim, *Clin. Infect. Dis.*, **2007**, 45:1290
- D.H. Kim, H.J. Kim, S.K. Park, S.J. Kong, Y.S. Kim, T.H. Kim, E.K. Kim, K.M. Lee, S.S. Lee, J.S. Park, W.J. Koh, C.H. Lee, T.S. Shim, *Am. J. Respir. Crit. Care Med.*, **2010**, 182:113
- L. Richeldi, M. Covi, G. Ferrara, F. Franco, P. Vailati, E. Meschiari, L.M. Fabbri, G. Velluti, *Monaldi Arch Chest Dis.*, **2002**, 57:39
- W.W. Yew, C.K. Chan, C.C. Leung, C.H. Chau, C.M. Tam, P.C. Wong, *Lee. J. Chest.*, **2003**, 124:1476
- C. Piersimoni, C. Lacchini, V. Penati, E. Iona, L. Fattorini, D. Nista, D. Zallocco, G.P. Gesu, L. Codecasa, *Diagn Microbiol Infect Dis.*, **2007**, 57:283
- R.A. Devasia, A. Blackman, C. May, S. Eden, T. Smith, N. Hooper, F. Maruri, C. Stratton, A. Shintani, T.R. Sterling, *J. Antimicrob Chemother.*, **2009**, 63:1173
- J.C. Rodríguez, L. Cebrián, M. López, M. Ruiz, I. Jiménez, G. Royo, *J. Antimicrob Che-mother.*, **2004**, 53:441
- T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, G.L. Drusano, *In-fect Dis.*, **2004**, 190:1642
- K.R. Jacobson, D.B. Tierney, C.Y. Jeon, C.D. Mitnick, M.B. Murray, *Clin. Infect. Dis.*, **2010**, 51:6
- J.J. Saukkonen, D.L. Cohn, R.M. Jasmer, S. Schenker, J.A. Jereb, C.M. Nolan, C.A. Peloquin, F.M. Gordin, D. Nunes, D.B. Strader, J. Bernardo, R. Venkataramanan, T.R. Sterling, *Am. J. Respir. Crit. Care Med.*, **2006**, 174:935
- S. Saigal, S.R. Agarwal, H.P. Nandeesh, S.K. Sarin, *J. Gastroenterol Hepatol*, **2001**, 16:1028
- A. Szklo, F.C. Mello, R.L. Guerra, S.E. Dorman, G.R. Muzy-de-Souza, M.B. Conde, *Int. J. Tuberc Lung Dis.*, **2007**, 11:775
- C.C. Ho, Y.C. Chen, F.C. Hu, C.J. Yu, P.C. Yang, K.T. Luh, *Clin. Infect. Dis.*, **2009**, 48:1526
- X.F. Zhang, Y. Lv, W.J. Xue, B. Wang, C. Liu, P.X. Tian, L. Yu, X.Y. Chen, X.M. Liu, *Transplant Proc.*, **2008**, 40:1382
- S. Bonora, A. Mondo, L. Trentini, A. Calcagno, A. Lucchini, G. Di Perri, *J. Infect.*, **2008**, 57:78
- Y. Shishido, N. Nagayama, K. Masuda, M. Baba, A. Tamura, H. Nagai, S. Akagawa, Y. Kawabe, K. Machida, A. Kurashima, H. Komatsu, H. Yotsumoto, *Kek-kaku*, **2003**, 78:683
- T. Onoda, K. Murakami, R. Eda, A. Hiraki, K. Makihata, K. Takao, K. Aoe, T. Maeda, H. Takeyama, *Kekkaku*, **2003**, 78:491
- H. Amano, M. Takamori, A. Fujita, K. Sakashita, K. Murata, M. Miyamoto, A. Wada, *Kekkaku*, 2009, 84:591

39. W.W. Yew, J. Lee, *Chest*, **1992**, 101:1741
40. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, J.H. Grosset, *Am. J. Respir. Crit. Care Med.*, **2004**, 169:421
41. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R.J. O'Brien, A.A. Vernon, R.E. Chaisson, W.R. Bishai, J.H. Grosset, *Am. J. Respir. Crit. Care Med.*, **2004**, 170:1131
42. Tuberculosis Research Centre (Indian Council of Medical Re-search). *Indian J Tuberc* **2002**, 49: 27–38.
43. W.J. Burman, S. Goldberg, J.L. Johnson, G. Muzanye, M. Engle, A.W. Mosher, S. Choudhri, C.L. Daley, S.S. Munsiff, Z. Zhao, A. Vernon, R.E. Chaisson, *Am. J. Respir. Crit. Care Med.*, **2006**, 174:331.
44. R. Rustomjee, C. Lienhardt, T. Kanyok, G.R. Davies, J. Levin, T. Mthiyane, C. Reddy, A.W. Sturm, F.A. Sirgel, J. Allen, D.J. Coleman, B. Fourie, D.A. Mitchison, *Int. J. Tuberc. Lung Dis.*, **2008**, 12:128
45. M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graça, M.C. Cezar, M. Ram, M.A. Chaudhary, W.R. Bishai, A.L. Kritski, R.E. Chaisson, *Lancet*, **2009**, 373:1183
46. S.E. Dorman, J.L. Johnson, S. Goldberg, G. Muzanye, N. Padayatchi, L. Bozeman, C.M. Heilig, J. Bernardo, S. Choudhri, J.H. Grosset, E. Guy, P. Guyadeen, M.C. Leus, G. Maltas, D. Menzies, E.L. Nuermberger, M. Villarino, A. Vernon, R.E. Chaisson, *Am. J. Respir. Crit. Care Med.*, **2009**, 180:273
47. J.Y. Wang, J.T. Wang, T.H. Tsai, C.L. Hsu, C.J. Yu, P.R. Hsueh, L.N. Lee, P.C. Yang, *Int. J. Tuberc Lung Dis.*, **2010**, 14:65
48. R.D. Gosling, L.O. Uiso, N.E. Sam, E. Bongard, E.G. Kanduma, M. Nyindo, R.W. Morris, S.H. Gillespie J, *Am. J. Respir. Crit. Care Med.*, **2003**, 168:1342
49. J.L. Johnson, D.J. Hadad, W.H. Boom, C.L. Daley, C.A. Peloquin, K.D. Eisenach, D.D. Jankus, S.M. Debanne, E.D. Charlebois, E. Maciel, M. Palaci, R. Dietze, *Int. J. Tuberc. Lung Dis.*, **2006**, 10: 605+-
50. I.M. Rosenthal, K. Williams, S. Tyagi, A.A. Vernon, C.A. Peloquin, W.R. Bishai, J.H. Grosset, E.L. 1` +WQ123Nuermberger, *Am. J. Respir. Crit. Care Med.*, **2005**, 172: 1457
51. I.M. Rosenthal, M. Zhang, K.N. Williams, C.A. Peloquin, S. Tyagi, A.A. Vernon, W.R. Bishai, R.E. Chaisson, J.H. Grosset, E.L. Nuermberger, *PLoS Med.*, **2007**, 4: e344.
52. F. Marra, C.A. Marra, S. Moadebi, P. Shi, R.K. Elwood, G. Stark, J.M. FitzGerald, *Chest.*, 2005, 128: 1406
53. W.W. Yew, C.H. Chau, J. Lee, *Int. J. Tuberc. Lung Dis.*, **2002**, 6: 1132.
54. K.C. Chang, C.C. Leung, W.W. Yew, F.M. Lam, P.L. Ho, C.H. Chau, V.C. Cheng, K.Y. Yuen, *Int. J. Tuberc. Lung Dis.*, **2009**, 13:341
55. C. Carbon, *Chemotherapy*, 2001, 47: 9
56. J. Morganroth, J.P. Dimarco, A. Anzue-to, M.S. Niederman, S. Choudhri, *Chest.*, **2005**, 128: 3398
57. P.B. Iannini, *Expert. Opin. Drug. Saf.*, **2002**, 1:121
58. L.Y. Park-Wyllie, D.N. Juurlink, A. Kopp, B.R. Shah, T.A. Stukel, C. Stumpo, L. Dresser, D.E. Low, M.M. Mamdani, *N. Engl. J. Med.*, **2006**, 354: 1352
59. D. Agrawal, Z.F. Udwadia, C. Rodri-guez, A. Mehta. *Int. J. Tuberc. Lung Dis.*, **2009**, 13:79
60. K.C. Chang, C.C. Leung, W.W. Yew, T.Y. Lau, W.M. Leung, C.M. Tam, H.C. Lam, P.S. Tse, M.Y. Wong, S.N. Lee, K.I. Wat, Y.H. Ma, *Eur. Respir. J.*, **2010**, 35:606
61. H.M. Nijland, R. Ruslami, A.J. Suroto, D.M. Burger, B. Alisjahbana, R. van Crevel, R.E. Aarnoutse, *Clin. Infect. Dis.*, **2007**, 45:1001
62. H. McIlleron, J. Norman, T.P. Kanyok, P.B. Fourie, J. Horton, P.J. Smith, *Antimicrob Chemother*, **2007**, 60:1398.
63. M. Asif, *J. Chem. Rev.*, **2019**, 1:47.
64. S. Sajjadifar, H. Hamidi, K. Pal, *J. Chem. Rev.*, **2019**, 1:35.
65. E.R. Nezhad, S. Sajjadifar, Z. Abbasi, S. Rezayati, *Journal of Sciences, Islamic Republic of Iran*, **2014**, 25:127.
66. D.F. Latona, *Adv. J. Chem. A*, **2019**, 2:225.
67. W.E. John, A.A. Ayi, C. Anyama, P.B. Ashishie, B.E. Inah, *Adv. J. Chem. A*, **2019**, 2:175.

How to cite this article: Mohammad Asif *, An Overviev on Fluoroquinolone Drugs for the Treatment of Tubercular Infection, *Journal of Medicinal and Chemical Sciences*, 2019, 2(4), 172-176. Link: http://www.jmchemsci.com/article_85469.html